Skip to main content

8 Result(s)

within José Moltó Remove this filter English Remove this filter

and

  1. Article

    Open Access

    Gut microbiome signatures linked to HIV-1 reservoir size and viremia control

    The potential role of the gut microbiome as a predictor of immune-mediated HIV-1 control in the absence of antiretroviral therapy (ART) is still unknown. In the BCN02 clinical trial, which combined the MVA.HIV...

    Alessandra Borgognone, Marc Noguera-Julian, Bruna Oriol, Laura Noël-Romas… in Microbiome (2022)

    Download PDF (4449 KB) View Article

  2. No Access

    Article

    Older Age is Associated with Higher Dolutegravir Exposure in Plasma and Cerebrospinal Fluid of People Living with HIV

    People living with human immunodeficiency virus are ageing under combination antiretroviral treatments but data on drug exposure in serum and cerebrospinal fluid are limited. Dolutegravir is a widely used seco...

    Andrea Calcagno, José Moltó, Alberto Borghetti… in Clinical Pharmacokinetics (2021)

  3. Article

    Open Access

    Ambrisentan use in a HIV-1 infected patient with end-stage renal disease and pulmonary hypertension: minimal removal by hemodialysis - a case report

    Ambrisentan is a selective endothelin receptor antagonist used for the treatment of pulmonary arterial hypertension (PAH). Little is known about ambrisentan removal by hemodialysis in patients with end-stage r...

    José Ramón Santos, Ana Merino, Walter E. Haefeli, Cristina Miranda… in BMC Nephrology (2020)

    Download PDF (482 KB) View Article

  4. No Access

    Chapter

    Clinical Pharmacology of the Synthetic Cathinone Mephedrone

    4-Methyl-N-methylcathinone (mephedrone) is a popular new psychoactive substance (NPS) that is structurally related to the parent compound cathinone, the β-keto analogue of amphetamine. Mephedrone appeared on the ...

    Esther Papaseit, José Moltó, Robert Muga… in Neuropharmacology of New Psychoactive Subs… (2017)

  5. No Access

    Article

    Simultaneous Pharmacogenetics-Based Population Pharmacokinetic Analysis of Darunavir and Ritonavir in HIV-Infected Patients

    Darunavir is a potent protease inhibitor of HIV. To enhance its pharmacokinetic profile, darunavir must be co-administered with ritonavir. There is wide inter-patient variability in darunavir pharmacokinetics ...

    José Moltó, George **narianos, Cristina Miranda… in Clinical Pharmacokinetics (2013)

  6. No Access

    Article

    Clinical Utility of Maraviroc

    Maraviroc belongs to the family of chemokine (C-C motif) receptor 5 (CCR5) antagonists that prevent the entry of human immunodeficiency virus (HIV) into host CD4+ T cells by blocking the CCR5 co-receptor R5. M...

    Jorge Parra, Joaquín Portilla, Dr Federico Pulido… in Clinical Drug Investigation (2011)

  7. No Access

    Article

    Interruptions of antiretroviral therapy in human immunodeficiency virus infection: are they detrimental to neurocognitive functioning?

    Because interruptions of antiretroviral treatment may entail clinical risks for human immunodeficiency virus (HIV)-infected individuals, we investigated their impact on neurocognitive functioning. Cross-sectio...

    Jose A. Muñoz-Moreno, Carmina R. Fumaz, Anna Prats… in Journal of NeuroVirology (2010)

  8. No Access

    Article

    Lopinavir/Ritonavir Pharmacokinetics in HIV and Hepatitis C Virus Co-Infected Patients without Liver Function Impairment

    Background and objective: To assess the influence of hepatitis C virus (HCV) co-infection and the extent of liver fibrosis on lopinavir/ritonavir pharmacokinetics in HIV-infected patients without...

    José Moltó, Marta Valle, Asuncion Blanco, Eugenia Negredo… in Clinical Pharmacokinetics (2007)